tert-butyl [2-hydroxy-1-(4-nitrobenzyl)ethyl]carbamate | 183669-13-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: tert-butyl [2-hydroxy-1-(4-nitrobenzyl)ethyl]carbamate
• 英文别名: (S)-2-(Boc-amino)-3-(4-nitrophenyl)-1-propanol；tert-butyl N-[1-hydroxy-3-(4-nitrophenyl)propan-2-yl]carbamate
• CAS: 183669-13-8
• 化学式: C₁₄H₂₀N₂O₅
• 分子量: 296.323
• InChiKey: KTPNZMCVUCJKMM-UHFFFAOYSA-N

物化性质

• 沸点：
  481.1±40.0 °C(Predicted)
• 密度：
  1.217±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  21
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  104
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  tert-butyl [2-hydroxy-1-(4-nitrobenzyl)ethyl]carbamate 在 草酰氯 、 sodium hydrogensulfite 、 二甲基亚砜 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 水 为溶剂， 反应 22.67h， 生成 tert-butyl (1-cyano-1-hydroxy-3-(4-nitrophenyl)propan-2-yl)carbamate
  参考文献：
  名称：

  [EN] ALIPHATIC PROLINAMIDE DERIVATIVES
  [FR] DÉRIVÉS DE PROLINAMIDE ALIPHATIQUE

  摘要：

  这项发明涉及一种新型的脂肪族脯氨酰胺衍生物，其化学式为I，并且包括药学上可接受的盐、溶剂化合物、盐的溶剂化合物和其前药，用于预防（例如，延缓或减少发展风险）和治疗（例如，控制、缓解或减缓进展）与眼睛相关的年龄相关性黄斑变性（AMD）及相关眼部疾病。这些疾病包括干性AMD、湿性AMD、地理性萎缩、糖尿病视网膜病变、早产儿视网膜病变、多发性脉络膜血管病变以及视网膜或光感受器细胞的退化。本公开的发明还涉及预防、减缓进展和治疗干性AMD、湿性AMD和地理性萎缩、糖尿病视网膜病变、早产儿视网膜病变、多发性脉络膜血管病变以及视网膜或光感受器细胞的方法，包括：给予所述发明化合物的治疗有效量。本发明的化合物是HTRAl的抑制剂。因此，本发明的化合物在预防和治疗一系列（全部或部分）由HTRAl介导的疾病中具有用途。本发明的化合物还可用于抑制眼部或关节炎或相关疾病部位的HTRAl蛋白酶活性。

  公开号：

  WO2017222917A1
• 作为产物：
  描述：

  2-amino-3-(4-nitrophenyl)propan-1-ol 、 2-(tert-butoxycarbonyloxyimino)-2-phenylacetonitrile 以 乙腈 为溶剂， 反应 4.0h， 以96%的产率得到tert-butyl [2-hydroxy-1-(4-nitrobenzyl)ethyl]carbamate
  参考文献：
  名称：

  Rational Design and Generation of a Bimodal Bifunctional Ligand for Antibody-Targeted Radiation Cancer Therapy

  摘要：

  An antibody-targeted radiation therapy (radioimmunotherapy, RIT) employs a bifunctional ligand that can effectively hold a cytotoxic metal with clinically acceptable complexation kinetics and stability while being attached to a tumor-specific antibody. Clinical exploration of the therapeutic potential of RIT has been challenged by the absence of adequate ligand, a critical component for enhancing the efficacy of the cancer therapy. To address this deficiency, the bifunctional ligand C-NETA in a unique structural class possessing both a macrocyclic cavity and a flexible acyclic moiety was designed. The practical, reproducible, and readily scalable synthetic route to C-NETA was developed, and its potential as the chelator of Bi-212, Bi-213, and Lu-177 for RIT was evaluated in vitro and in vivo. C-NETA rapidly binds both Lu(III) and Bi(III), and the respective metal complexes remain extremely stable in serum for 14 days. Lu-177-C-NETA and Bi-205/6-C-NETA possess an excellent or acceptable in vivo biodistribution profile.

  DOI：

  10.1021/jm070401q

文献信息

• 양전자 방출 단층 촬영용 화합물
  申请人：ENDOCYTE, INC. 엔도사이트, 인코포레이티드(520040372060)

  公开号：KR20160079887A

  公开（公告）日：2016-07-06

  본원에 개시된 것은 양전자 방출 단층 촬영을 이용하여 병원성 질환을 진단 및/또는 모니터링하기 위한 화합물, 조성물 및 방법이다. 또한 개시된 것은 B가 비타민 수용체 결합 리간드 (예컨대 폴레이트), PSMA 결합 리간드 또는 PSMA 억제제로부터 선택되는 표적화제의 라디칼이며; L이 아스파르트산, 라이신, 또는 아르기닌을 포함하는 2가 링커이고; P가 조영제 또는 방사선 요법제, 예컨대 방사성 핵종 또는 방사성 핵종 함유 기의 라디칼, 또는 방사성 핵종, 예컨대 금속 킬레이팅 기에 결합할 수 있는 화합물의 라디칼인 화학식 B-L-P의 콘쥬게이트이다.

  本发明涉及利用正电子发射断层扫描诊断和/或监测病原性疾病的化合物、组合物和方法。此外，所述的是B是维生素受体结合配体（例如聚谷酸）、PSMA结合配体或PSMA抑制剂中选择的靶向剂的基团；L是包含天冬氨酸、赖氨酸或精氨酸的2价连接基；P是造影剂或放射治疗剂，例如放射性核素或含有放射性核素的基团，或者是可与放射性核素，例如金属螯合基结合的化合物的基团的化学式B-L-P的共轭物。
• Bimodal ligands with macrocyclic and acyclic binding moieties, complexes and compositions thereof, and methods of using
  申请人：Chong Hyun-soon

  公开号：US09115094B2

  公开（公告）日：2015-08-25

  Substituted 1,4,7-triazacyclononane-N,N′,N″-triacetic acid and 1,4,7,10-tetraazacyclcododecane-N,N′,N″,N′″-tetraacetic acid compounds with a pendant amino or hydroxyl group, metal complexes thereof, compositions thereof, and methods of making and use in diagnostic imaging and treatment of cellular disorders.

  用带有氨基或羟基的1,4,7-三氮杂环壬烷-N,N′,N″-三乙酸和1,4,7,10-四氮杂环十二烷-N,N′,N″,N′″-四乙酸化合物替代，以及它们的金属配合物、组合物、制备方法以及在诊断成像和治疗细胞疾病中的应用。
• O-carbamoyl-phenylalaninol compounds, their pharmaceutically useful
  申请人：Yukong Limited

  公开号：US05756817A1

  公开（公告）日：1998-05-26

  The present invention relates to a racemic or enantiomerically enriched O-carbamoyl-phenylalaninol compound represented by the following structural formula V and pharmaceutically acceptable salts thereof to treat diseases of the central nervous system: ##STR1## wherein Ph is a phenyl group as described as follows: ##STR2## wherein R is a member selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, halogen selected from F, Cl, Br and I, alkoxy containing 1 to 3 carbon atoms, nitro, hydroxy, trifluoromethyl, and thioalkoxy containing 1 to 3 carbon atoms, and x is an integer from 1 to 3, with the proviso that R is the same or different when x is 2 or 3, R.sup.1 and R.sup.2 may be the same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, aryl, arylalkyl, cyclic propyl and 5 to 7-membered aliphatic cyclic compounds, and R.sup.1 and R.sup.2 may be joined to form a 5 to 7-membered cyclic compound which may comprise zero to one additional nitrogen atom substituted with a member selected from the group consisting of hydrogen, alkyl, and aryl groups, or zero to one oxygen atom directly unconnected, excluding the instance where R, R.sup.1, and R.sup.2 are all hydrogen, and the pharmaceutically acceptable salts thereof. The present invention also relates to O-carbamoyl-(D)-phenylalaninol compounds, represented by the following structural formula IX: ##STR3## wherein Ph, R.sup.1, and R.sup.2 are as described above, and the pharmaceutically acceptable salts thereof.

  本发明涉及一种立体混合物或对映富集的O-氨甲酰-苯丙氨醇化合物，其结构式如下所示，并其药学上可接受的盐，用于治疗中枢神经系统疾病：其中Ph是如下描述的苯基，其中R是从氢、碳原子数为1至8的低碳烷基、选择的卤素F、Cl、Br和I、含有1至3个碳原子的烷氧基、硝基、羟基、三氟甲基和含有1至3个碳原子的硫代烷氧基中选择的成员，x为1至3的整数，但R是当x为2或3时相同时或不同时，R.sup.1和R.sup.2可以相同也可以不同，并且分别选择自氢、碳原子数为1至8的低碳烷基、芳基、芳基烷基、环丙基和5至7成员的脂肪环化合物的群中，R.sup.1和R.sup.2可以连接形成5至7成员的环化合物，该环化合物可以包含零至一个额外氮原子，该氮原子被氢、烷基和芳基群中选择的成员取代，或零至一个直接未连接的氧原子，但不包括R、R.sup.1和R.sup.2均为氢时的情况，以及其药学上可接受的盐。本发明还涉及O-氨甲酰-(D)-苯丙氨醇化合物，其结构式如下所示：其中Ph、R.sup.1和R.sup.2如上述描述，并且其药学上可接受的盐。
• O-carbamoyl-phenylalaninol having substituent at benzene ring, its
  申请人：SK Corporation

  公开号：US06140532A1

  公开（公告）日：2000-10-31

  O-Carbamoyl-phenylalaninol having substituent at benzene ring, represented by the general formula I, and pharmaceutically useful salts thereof, which are useful for the prophylaxis and treatment of CNS disorder including depression and anxiety, are disclosed: ##STR1## wherein R is lower alkyl containing 1 to 8 carbon atoms, halogen such as F, Cl and I, alkoxy containing 1 to 3 carbon atoms, thioalkoxy containing 1 to 3 carbon atoms, nitro, hydroxy, or trifluorocarbon, and x is an integer of 1 to 3, with a proviso that R is the same or different when x is 2 or 3.

  本发明公开了具有苯环上取代基的O-氨基甲酰基苯丙氨醇，其通式为I，以及其药学上有用的盐，可用于预防和治疗包括抑郁症和焦虑症在内的中枢神经系统疾病：##STR1## 其中R是含有1至8个碳原子的低级烷基，如F、Cl和I的卤素，含有1至3个碳原子的烷氧基，含有1至3个碳原子的硫代烷氧基，硝基，羟基或三氟甲基，x是1至3的整数，具有这样的前提条件，即当x为2或3时，R是相同或不同的。
• Design, Synthesis, and Biological Evaluation of Polyaminocarboxylate Ligand-Based Theranostic Conjugates for Antibody-Targeted Cancer Therapy and Near-Infrared Optical Imaging
  作者：Siyuan Ren、Xiang Sun、Haixing Wang、Trung Hai Nguyen、Negar Sadeghipour、Xiaochun Xu、Chi Soo Kang、Yujie Liu、Hua Xu、Ningjie Wu、Yanda Chen、Kenneth Tichauer、David D. L. Minh、Hyun-Soon Chong

  DOI：10.1002/cmdc.201800598

  日期：2018.12.20

  We report the design, synthesis, and evaluation of polyaminocarboxylate ligand‐based antibody conjugates for potential application in targeted cancer therapy and near‐infrared (NIR) fluorescence imaging. We synthesized a new polyaminocarboxylate chelate (CAB‐NE3TA) as a potential anticancer agent. CAB‐NE3TA displayed potent inhibitory activities against various cancer cell lines. We then designed a

  我们报告了基于聚氨基羧酸酯配体的抗体缀合物的设计、合成和评估，其在靶向癌症治疗和近红外（NIR）荧光成像中的潜在应用。我们合成了一种新的聚氨基羧酸螯合物（CAB-NE3TA）作为潜在的抗癌剂。 CAB-NE3TA 对多种癌细胞系表现出有效的抑制活性。然后，我们设计了一个多功能治疗诊断平台（CAB-NE3TA-PAN-IR800），该平台基于用近红外荧光染料标记的表皮生长因子受体（EGFR）靶向抗体（帕尼单抗，PAN）构建。我们还构建了 EGFR-PAN 复合物的第一个原子模型，并为其加载了细胞毒性 CAB-NE3TA 和近红外染料。使用 EGFR 阳性 A431（人皮肤癌）细胞异种移植小鼠模型对治疗 (CAB-NE3TA-PAN) 和治疗诊断 (CAB-NE3TA-PAN-IR800) 缀合物进行评估。使用近红外荧光成像的生物分布研究表明，用 IR800 染料标记的 CAB-NE3TA-PAN